Version May 2024
Note: Measure dose with appropriate radioactivity calibration system immediately prior to administration.
Renal function and imaging: IV (based on 70 kg patient): 5 to 10 mCi (185 to 370 MBq)
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
Refer to adult dosing.
(For additional information see "Technetium Tc-99m mertiatide: Pediatric drug information")
Note: Measure dose with appropriate radioactivity calibration system immediately prior to administration.
Renal function assessment and imaging: Infants, Children, and Adolescents: IV: 70 to 140 μCi/kg (2.6 to 5.2 MBq/kg); minimum dose: 1 mCi (37 MBq).
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
Frequency not defined.
Cardiovascular: Hypertension, tachycardia
Central nervous system: Chills, seizure
Dermatologic: Pruritus, skin rash
Gastrointestinal: Nausea, vomiting
Respiratory: Dyspnea, wheezing
Miscellaneous: Fever
There are no contraindications listed in the manufacturer’s labeling.
Special handling:
• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and health care personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.
Other warnings/precautions:
• Appropriate use: Patients should be adequately hydrated prior to dosing; instruct patients to void frequently for 6 hours following administration to decrease radiation exposure to the bladder.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Injection, Powder for Reconstitution [kit]:
TechneScan MAG3: Betiatide 1 mg (5s) (to be combined with sodium pertechnetate Tc99m injection solution [not included])
No
IV: Not for direct IV injection; only reconstituted technetium Tc 99m mertiatide may be administered IV. See manufacturer’s prescribing information for complete administration procedure. Ensure adequate hydration before and after administration; void frequently for 4 to 6 hours post administration to minimize bladder exposure.
Radiopharmaceutical; use appropriate precautions for handling and disposal. Use waterproof gloves and effective radiation shielding when handling.
Radiopharmaceutical; use appropriate precautions for handling and disposal. Use waterproof gloves and effective radiation shielding when handling.
IV: Not for direct IV injection; only reconstituted technetium Tc 99m mertiatide may be administered IV. See manufacturer's labeling for complete administration procedure. Ensure adequate hydration before and after administration; void frequently for 6 hours post administration to minimize bladder exposure.
Renal function and imaging: Radiopharmaceutical imaging agent used in the diagnosis of congenital and acquired abnormalities, renal failure, urinary tract obstruction, and calculi. It provides renal function, split function, renal angiograms, and renogram curves for whole kidney and renal cortex.
Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.
None known.
There are no known significant interactions.
Pregnancy status should be evaluated prior to use in women of reproductive potential (SNM 2010).
Unbound technetium crosses the placenta. Technetium Tc 99m can be detected in fetal tissue; the amount depends on the specific formulation, route of administration, and stage of pregnancy (Adelstein 1999).
In general, the potential for a radiopharmaceutical to cause fetal harm depends on the dose absorbed by the fetus and the stage of pregnancy. High doses of radiopharmaceuticals used for therapeutic procedures are more likely to result in fetal harm. A medically required diagnostic procedure can usually be modified to decrease fetal risk. Elective diagnostic procedures should be delayed until after delivery (ACR-SPR 2018; Adelstein 1999; ICRP 2000; SNM 2010).
Technetium Tc 99m is present in breast milk.
An interruption of breastfeeding may not always be required (ABM [Mitchell 2019]), however, expressing and discarding breast milk for a period of 4 hours following technetium Tc 99m mertiatide for imaging of the kidneys and urinary tract may be considered (IAEA 2018). During the period of breastfeeding interruption, the manufacturer recommends substituting formula for breast milk. Alternatively, women can pump and store breast milk prior to the procedure, which can be bottle-fed (Harding 1995).
Elective diagnostic procedures should be delayed until breastfeeding has stopped (SNM 2010). Women who are breastfeeding and caring for individuals undergoing nuclear medicine procedures do not need any additional precautions (ABM [Mitchell 2019]).
Excretion of technetium Tc 99m into colostrum is widely variable and information is limited; therefore, recommendations related to early breastfeeding cannot be made (Mountford 1989; Rubow 1994).
Protein binding: 78% to 89%
Half-life elimination: 6.02 hours
Excretion: Urine (~90%); clearance: 0.03 to 0.3 L/minute
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
